Patents by Inventor Thomas M. Stormann

Thomas M. Stormann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of mGluR5 antagonists for the treatment of gerd
    Patent number: 7964609
    Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Anders Lehmann, Jan Mattsson, Thomas M. Stormann
  • Compounds
    Patent number: 7456200
    Abstract: The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: November 25, 2008
    Assignee: Astrazeneca AB
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tomislav Stefanac, Thomas M. Stormann, David Wensbo, Tao Xin, Helena Gyback, Martin Johansson, Annika Kers, John Malmberg, Alexander Minidis, Karin Oscarsson, Mangus Waldman, Ulrika Yngve, Christoffer Osterwall
  • G-protein fusion receptors and constructs encoding same
    Patent number: 7262280
    Abstract: The present invention features G-protein fusion receptors and chimeric GABAB receptors (GABABRs), nucleic acid encoding such receptors, and the use of such receptors and nucleic acid. G-protein fusion receptors comprise at least one domain from a CaR, an mGluR, and/or a GABAB receptor fused directly or through a linker to a guanine nucleotide-binding protein (G-protein). Chimeric GABABRs comprise at least one of a GABABR extracellular domain, a GABABR transmembrane domain, or a GABABR intracellular domain and one or more domains from a mGluR subtype 8 (mGluR8) and/or a CaR.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: August 28, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Lance G. Hammerland, Laura L. Storjohann, James G. Busby, James E. Garrett, Rachel T. Simin
  • Human metabotropic glutamate receptor
    Patent number: 7241863
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR, as well as compounds that modulate mGluR activity, may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: July 10, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland, Laura Storjohann
  • Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    Patent number: 7112595
    Abstract: The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: September 26, 2006
    Assignees: NPS Pharmaceuticals, Inc., Astrazeneca AB
    Inventors: Bradford Van Wagenen, Thomas M. Stormann, Scott T Moe, Susan M Sheehan, Donald McLeod, Daryl L Smith, Methvin Isaac, Abdelmalik Slassi, Ian Egle, Louise Edwards, Tomislav Stefanac, Tao Xin, Jalaj Arora, William Michne
  • Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
    Patent number: 7053104
    Abstract: The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: May 30, 2006
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Bradford C. Van Wagenen, Scott T. Moe, Daryl L. Smith, Susan M. Sheehan, Irina Shcherbakova, Ruth Walton, Richard Trovato, Robert Barmore, Eric G. Delmar, Thomas M. Stormann
  • Compounds
    Publication number: 20040152699
    Abstract: The present invention relates to new compounds of formula I, 1
    Type: Application
    Filed: August 8, 2003
    Publication date: August 5, 2004
    Applicant: AstraZeneca and NPS Pharmaceuticals, Inc.
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tomislav Stefanac, Thomas M. Stormann, David Wensbo, Tao Xin, Helena Gyback, Martin Johansson, Annika Kers, John Malmberg, Alexander Minidis, Karin Oscarsson, Mangus Waldman, Ulrika Yngve, Christoffer Osterwall
  • New compounds
    Publication number: 20040132726
    Abstract: The present invention relates to new compounds of formula I, 1
    Type: Application
    Filed: August 8, 2003
    Publication date: July 8, 2004
    Applicant: AstraZeneca AB and NPS Pharmaceuticals, Inc.
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tomislav Stefanac, Thomas M. Stormann, David Wensbo, Tao Xin, Annika Kers, Johan Malmberg, Karin Oscarsson
  • Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    Patent number: 6660753
    Abstract: The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: December 9, 2003
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Bradford Van Wagenen, Thomas M. Stormann, Scott T. Moe, Susan M. Sheehan, Donald A. McLeod, Daryl L. Smith, Methvin Benjamin Isaac, Abdelmalik Slassi
  • Novel human metabotropic glutamate receptor
    Publication number: 20030157647
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Application
    Filed: January 17, 2003
    Publication date: August 21, 2003
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland, Laura Storjohann
  • Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
    Publication number: 20030113873
    Abstract: The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors.
    Type: Application
    Filed: November 19, 2002
    Publication date: June 19, 2003
    Applicant: NPS Pharmaceuticals
    Inventors: Forrest H. Fuller, Lance G. Hammerland, Karen J. Krapcho, Laura L. Storjohann, Thomas M. Stormann
  • Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    Publication number: 20030055085
    Abstract: The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Application
    Filed: February 19, 2002
    Publication date: March 20, 2003
    Inventors: Bradford Van Wagenen, Thomas M. Stormann, Scott T. Moe, Susan M. Sheehan, Donald A. McLeod, Daryl L. Smith, Methvin Benjamin Isaac, Abdelmalik Slassi
  • Human metabotropic glutamate receptor
    Patent number: 6534287
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: March 18, 2003
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland
  • Nucleic acids encoding mGLuR/CaR chimera
    Patent number: 6534289
    Abstract: The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors. The invention also relates to compounds and methods for modulating metabotropic glutamate receptor activity and binding to metabotropic glutamate receptors. Modulation of metabotropic glutamate receptor activity can be used for different purposes such as treating neurological disorders and diseases, inducing an analgesic effect, cognition enhancement, and inducing a muscle-relaxant effect.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: March 18, 2003
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Forrest H. Fuller, Karen J. Krapcho, Lance G. Hammerland, Laura L. Storjohann, Thomas M. Stormann
  • Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
    Publication number: 20030013715
    Abstract: The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Application
    Filed: August 5, 2002
    Publication date: January 16, 2003
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Bradford C. Van Wagenen, Scott T. Moe, Daryl L. Smith, Susan M. Sheehan, Irina Shcherbakova, Ruth Walton, Richard Trovato, Robert Barmore, Eric G. Delmar, Thomas M. Stormann
  • Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
    Patent number: 6429207
    Abstract: The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: August 6, 2002
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Bradford C. Van Wagenen, Scott T. Moe, Daryl L. Smith, Susan M. Sheehan, Irina Shcherbakova, Richard Travato, Ruth Walton, Robert Barmore, Eric G. Delmar, Thomas M. Stormann
  • Cloned genes for human dopamine D2 receptors and cell lines expressing same
    Patent number: 6214615
    Abstract: Disclosed herein is an isolated or essentially pure DNA sequence encoding a human Dopamine D2 receptor, the protein comprising the receptor, vectors for transforming or transfecting host cells with such DNA so that the cells express the DNA, methods of obtaining the DNA and preparing the transformed or transfected cells and cell lines, and methods of using the cells and cell lines in assays for the determination of human dopamine D2 receptor antagonists or agonists.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: April 10, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark R. Brann, Thomas M. Stormann
  • Human metabotropic glutamate receptor
    Patent number: 6084084
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: July 4, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Rachel T. Simin, Lance G. Hammerland, Forrest H. Fuller
  • Human metabotropic glutamate receptor
    Patent number: 6077675
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: June 20, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Rachel T. Simin, Lance G. Hammerland, Forrest H. Fuller
  • Isolated human metabotropic glutamate receptor Mglur-8
    Patent number: 6051688
    Abstract: A human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: April 18, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Rachel T. Simin, Lance G. Hammerland, Forrest H. Fuller